• 1
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 10291035.
  • 2
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340: 13981405.
  • 3
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117: 761769.
  • 4
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876885.
  • 5
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 15411549.
  • 6
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323333.
  • 7
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228238.
  • 8
    Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. Ann Intern Med. 2007; 146: 829838.
  • 9
    Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 12321239.
  • 10
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239250 [correction, N Engl J Med 2007;357:1357].
  • 11
    Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 5265.
  • 12
    Remicade [prescribing information]. Malvern, PA: Centocor; 2008.
  • 13
    Humira [prescribing information]. North Chicago, IL: Abbott Laboratories; 2008.
  • 14
    Cimzia [prescribing information]. Smyrna, GA: UCB; 2008.
  • 15
    Sandborn WJ, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Am J Gastroenterol. 2008; (suppl 1): S436. Presented at: American College of Gastroenterology Scientific Meeting; October 3–8, 2008; Orlando, FL.
  • 16
    D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660667.
  • 17
    Hibi T, Watanabe M, Camez A, et al. Efficacy and safety of adalimumab for the treatment of Japanese patients with moderately to severely active Crohn's disease: results from a randomized controlled trial. Am J Gastroenterol. 2008; 103( suppl 1): S414S415.
  • 18
    Lofberg R, Louis E, Reinisch W, et al. Adalimumab effectiveness in TNF-antagonist-naïve patients and in infliximab nonresponders with Crohn's disease: results from the CARE study. Am J Gastroenterol. 2008; 103( suppl 1): S418.
  • 19
    Lichtiger S, Binion DG, Wolf DC, et al. Adalimumab safety in patients with Crohn's disease and previous exposure to infliximab: CHOICE trial. Gastroenterology. 2008; 134( 4 suppl 1): A-489.
  • 20
    Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline for industry-clinical safety data management: definitions and standards for expedited reporting. FDA Center for Drug Evaluation and Research. Available at: Accessed April 9, 2009.
  • 21
    Breslow NE, Day NE. Statistical methods in cancer research: vol II. The design and analysis of cohort studies. International Agency for Research on Cancer. New York: Oxford University Press; 1987: 1406.
  • 22
    Surveillance Epidemiology and End Results [database online]. Bethesda, MD: National Cancer Institute; 2007.
  • 23
    Scotto J, Fears TR, Fraumeni JFJr. Incidence of non-melanoma skin cancer in the United States. US Department of Health and Human Services, Public Health Service, NIH, NCI, Pub No (NIH) 82-2433; Bethesda, MD: 1981.
  • 24
    Mortality Database [database online]. Geneva, Switzerland: World Health Organization; 2006.
  • 25
    Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 644653.
  • 26
    Burmester GR, Mease P, Dijkmans BAC, et al. Adalimumab safety and mortality rates from trials of six immune mediated inflammatory diseases. Ann Rheum Dis. doi:10.1136/ard.2008.102103.
  • 27
    Sands BE. Crohn's disease. In: Feldman et al, eds. Sleisenger & Fordtran's gastrointestinal and liver disease, 8th ed, vol 2. Philadelphia: Saunders Elsevier; 2006: 24592498.
  • 28
    Colombel JF, Loftus EVJr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126: 1931.
  • 29
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4: 621630.
  • 30
    Toruner M, Loftus EVJr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 143: 929938.
  • 31
    Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001; 344: 975983.
  • 32
    Humira [summary of product characteristics]. Kent, UK: Abbott Laboratories. Available at: Accessed April 9, 2009.
  • 33
    von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum. 2007; 50: 839855.
  • 34
    Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54: 11211125.
  • 35
    Jones JL, Loftus EVJr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis. 2007; 13: 12991307.
  • 36
    Ward EM, Thun MJ, Hannan LM, et al. Interpreting cancer trends. Ann N Y Acad Sci. 2006; 1076: 2953.
  • 37
    Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment Pharmacol Ther. 2007; 25: 861870.
  • 38
    Schreiber S, Reinisch W, Colombel JF, et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterolory. 2007; 132(4 Suppl 2): A-147. Presented at: Digestive Disease Week; May 19–24, 2007; Washington, DC.
  • 39
    Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135: 14939.
  • 40
    Colombel JF, Schwartz DA, Sandborn, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. doi:10.1136/gut.2008.159251.
  • 41
    Sandborn WJ, Hanauer S, Loftus EVJr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004; 99: 19841989.
    Direct Link:
  • 42
    Stallmach A, Giese T, Schmidt C, et al. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab-report of a case. Eur J Gastroenterol Hepatol. 2004; 16: 627630.
  • 43
    Youdim A, Vasikiauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004; 10: 333338.
  • 44
    Barthel HR, Gille T, Halbsguth A, et al. Successful treatment with adalimumab in infliximab-resistant Crohn's disease. J Gastroenterol Hepatol. 2005; 20, 14641465.
  • 45
    Papadakis K, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005; 100: 7579.
    Direct Link: